GlassScriptPhysician profile
Danielle Goolsby
NPI 1568088177
$1,781.56
in general payments reported to CMS, 2019-2025
21 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $362 · 2022: $242 · 2023: $510 · 2024: $217 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,177.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $557.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $166.14 | 2021-2025 | Mounjaro |
| Alkermes, INC. | $116.34 | 2022-2023 | Vivitrol |
| Astrazeneca Pharmaceuticals LP | $106.34 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Corcept Therapeutics | $103.73 | 2023-2025 | Korlym |
| Gilead Sciences, INC. | $95.18 | 2021-2023 | |
| Abbvie INC. | $87.28 | 2022-2025 | |
| Grifols USA, LLC | $86.19 | 2022-2023 | Prolastin-C Liquid, Xembify |
| Merck Sharp & Dohme LLC | $79.86 | 2021-2023 | Dificid, Zerbaxa, Recarbrio |
| Amgen INC. | $74.59 | 2023-2025 | Repatha, Otezla, Repatha |
| Sanofi Pasteur INC. | $59.95 | 2021-2022 | |
| Tempus Ai, INC | $41.07 | 2024 | |
| Exact Sciences Corporation | $37.13 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $32.37 | 2021 | |
| Daiichi Sankyo INC. | $24.00 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.39 | 2025 | |
| Edwards Lifesciences Corporation | $20.76 | 2025 | |
| Astellas Pharma US INC | $19.82 | 2025 | Veozah |
| Phadia US INC. | $19.44 | 2023 | Immunocap |
| Neurocrine Biosciences, INC. | $16.40 | 2024 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $15.35 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Goolsby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.